A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinectics of PLN-74809 in participants with idiopathic pulmonary fibrosis.

  • Glaspole, Ian (Primary Chief Investigator (PCI))
  • Symons, Karen M. (Project Manager)
  • Corte, Tamera Jo (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date1/12/2031/12/23


  • Respiratory medicine
  • Idiopathic pulmonary fibrosis
  • Clinical trial